Ionis Pharmaceuticals (IONS) AGM 2026 summary

Strategic transformation and commercial progress

• Transitioned from R&D-focused to fully integrated commercial-stage biotech, enabling independent launches and revenue growth.

• Achieved six positive phase III readouts and four approved medicines in three years, with three more approvals expected by year-end.

• Independent launches of TRYNGOLZA for FCS and DAWNZERA for hereditary angioedema are gaining strong momentum, with TRYNGOLZA reaching $27 million and DAWNZERA $16 million in Q1 2026.

• Four independent launches planned for 2025-2026, with five partner launches by end of 2027.

• On track for three new product launches this year, including olezarsen for SHTG, ZOLGENSMA for Alexander disease, and bepirovirsen for chronic HBV.

Pipeline innovation and clinical milestones

• Robust late-stage pipeline with 11 cardiometabolic and 13 neurology medicines in clinical development.

• Groundbreaking phase III data for olezarsen in SHTG showed 85% reduction in acute pancreatitis and normalization of triglycerides in many patients.

• Zilganersen for Alexander disease and obudanersen for Angelman syndrome advancing, with pivotal data and launches expected in the next year.

• Multiple partnered programs with AstraZeneca, Novartis, Biogen, and GSK, including upcoming phase III data for pelacarsen, eplontersen, and ulefnersen.

• First-in-class medicines for rare and prevalent diseases, with several programs receiving breakthrough therapy and priority review designations.

Financial outlook and growth guidance

• Peak annual product revenue from near-term launches expected to exceed $5 billion, with over $2 billion in royalty revenue, totaling more than $7 billion.

• Revenue guidance is probabilized, reflecting conservative assumptions on program success.

• On track to achieve break-even cash flow in 2028, with accelerating positive cash flow thereafter.

• Strong financial position supported by disciplined expense management and expanding commercial footprint.

• Clear path to sustained positive cash flow by 2027-2028, driven by new product launches and growing royalty revenue.